The ICAM‐MMP‐adalimumab aDVD was able to selectively target the human inflamed synovium from both the RA patients and the OA patients with similar efficacy as compared to an anti–ICAM‐1 IgG antibody. This evidence concerns the gene ICAM1 and rheumatoid arthritis.